Tibaldi J, et al. - In routine US clinical practice, researchers compared the real-world effectiveness of insulin degludec (degludec) vs glargine 300 units/mL (glargine U300) in insulin-naïve adult patients with type 2 diabetes. The primary endpoint, HbA1c change from baseline to 180 days of follow-up, was estimated using a repeated-measure of covariance analysis with subjects as a random effect. Using negative binomial and logistic regression, change in the rate of hypoglycemic episodes and change in proportion of patients with hypoglycemia were estimated. Data were analyzed for 4,056 patients. The results obtained from the CONFIRM (Clinical Outcome assessmeNt of the eFfectiveness of Insulin degludec in Real-life Medical practice) study indicate that degludec treatment results in significantly greater reductions in HbA1c with a 30% lower risk of hypoglycemia and reduced likelihood of discontinuation of treatment vs glargine U300.